Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Reexamination Certificate
2007-07-10
2007-07-10
Saidha, Tekchand (Department: 1652)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
C424S094600, C424S094610, C435S069100, C435S183000, C435S195000, C435S200000, C435S201000
Reexamination Certificate
active
10733501
ABSTRACT:
The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.
REFERENCES:
patent: 5179023 (1993-01-01), Calhoun et al.
patent: 5658567 (1997-08-01), Calhoun et al.
patent: 5762939 (1998-06-01), Smith et al.
patent: 6183987 (2001-02-01), van de Wiel et al.
patent: 6225060 (2001-05-01), Clark et al.
patent: WO 00/39150 (2000-07-01), None
Aeed, P.A. et al, “Glycosylationof recombinant prorenin in insect cells: the insect cell line Sf9 does not express the mannose 6-phosphate recognition signal”,Biochemistry 33(29):8793-97 (1994).
Aoki, M. et al, “Improvement of neurological symptoms by enzyme replacement therapy for Gaucher Disease Type IIIb”,Eur. J. Pediatr., 160(1): 63-64 (2001).
Berg, T. et al, “Purification and characterization of recombinant human lysosomal alpha-mannosidase”,Mol Genet Metab., 73(1):18-29 (2001).
Bijsterbosch, M.K. et al, “Quantitative analysis of the targeting of mannose-terminal glucocerebrosida; Prodominant uptake by liver endothelial cells”,Eur. J. Biochem, 237:344-349 (1996).
Bonten, E.J. et al, “Lysosomal Protective Protein/Cathepsin A”Journal of Biological Chemistry 270(44):26441-26445 (1995).
Bonten, E.J. et al, “Catalytic Activation in Insect Cells is Controlled by the Protective Protein/Cathepsin A”,Journal of Biological Chemistry 275(48): 37657-37663 (2000).
Bonten, E.J. et al, “Correction of lysosomal PPCA and neuraminidase in mouse deficient macrophages after uptake of recombinant baculovirus-expressed proteins”,Amer. J. Hum. Gen. Suppl. 69(4):Abst 1759 (2001).
Boose, J.A. et al, “Synthesis of a human lysosomal enzyme, beta-hexosaminidase B, using the baculovirus expression system”,Protein Expr. Purif. 1(2):111-20 (1990).
Bromme, D. et al, “High level expression and crystallization of recombinant human cathepsin S”,Protein Sci., 5(4):789-91 (1996).
Calhoun, D.H. et al, “Fabry disease: Isolation of a cDNA clone encoding human α-galactosidase A”,PNAS 82:7364-68 (1985).
Chen, Y. et al; “Purification and Characterization of Human α-Galactosidase A Expressed in Insect Cells Using a Baculovirus Vector”,Protein Expression and Purification 20:228-236 (2000).
Coppola, G. et al, “Characterization of glycosylated and catalytically active recombinant human alpha-Galactosidase A using a baculovirus vector”,Gene 144(2):197-203 (1994).
D'Azzo, A., “Biochemical properties of PPCA and neuraminidase”, Presentation at Strategies for Therapy of MPS and Related Diseases and 16thAnnual MPS Conference held on Jun. 22, 2001 at UCLA.
Davidson, D.J. et al; “Oligosaccharide Processing in the Expression of Human Plasminogen cDNA by Lepidopteran Insect (Spodoptera frugiperda) Cells”,Biochemistry 29(23): 5584-5590 (1990).
Davidson, D.J. et al; “Asparagine-Linked Oligosaccharide Processing in Lepidopteran Insect Cells. Tempor Dependence of the Naturs of the Oligosaccharides Assembled on Asparagine-289 of Recombinant Human Plasminogen Produced in Baculovirus Vector InfectedSpodoptera frugiperda(IPBL-SF-21AE) Cells”,Biochemistry 30(25): 6167-6174 (1991).
Davis, T.R. et al; “Intrinsic Glycosylation Potentials of Insect Cell Cultures and Insect Larvae”, In vitroCell. Dev.Biol. 31:659-663 (1995).
Desnick, R.J. “Enzyme replacement and beyond”,J Inherit Metab Dis. 24(2):251-65 (2001).
Eng, C.M. et al, “A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies”,Am. J. Hum. Genet., 68(3): 711-22 (2001).
Hahn, C.N. et al., “Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter”,PNAS 95:14880-85 (1998).
Hollister, J.R. et al, “Engineering lepidopteran insect for sialoglycoprotein production by genetic transformation with mammalian β1,4-galactosyltransferase and α2,6-sialyltransferase genes”,Glycobiology 11: 1-9 (2001).
Hsu, T. et al, “DifferentialN-Glycan Patterns of Secreted and Intracellular lgG Produced inTrichoplusia nicells”,Journal of Biological Chemistry 272(14): 9062-9070 (1997).
Ida, H. et al, “Effects of enzyme replacement therapy in thirteen Japanese pediatric patients with Gaucher Disease”,Eur. J. Pediatr. 106(1): 21-5 (2001).
Ioannou, Y.A. et al, “Fabry disease; preclinical studies demonstrate the effectiveness of alpha-galactosidase a replacement in enzyme-deficient mice”,Am. J. Hum. Genet. 68(1): 14-25 (2001).
Jarvis, D.L. et al, “Biochemical Analysis of the N-Glycosylation Pathway in Baculovirus-Infected Lepidopteran Insect Cells”,Virology 212: 500-511 (1995).
Jarvis, D.L. et al; “Modifying the insect cell N-glycosylation pathway with immediate early baculovirus Expression vectors”,Nature Biotechnology 14:1288-1292 (1996).
Jarvis, D.L. et al; “Engineering N-glycosylation pathways in the baculovirus-insect cell system”,Current Opinion in Biotechnology 9: 528-533 (1998).
Jarvis, D.L. et al; “Mutational Analysis of the N-Linked Glycans onAutographa californicaNucleopolyhedrovirus gp64”,Journal of Virology 72(12): 9459-9469 (1998).
Jarvis, D.L. et al, “Novel baculovirus expression vectors that proavide sialylation of recombinant glycoproteins in lepidopteran insect cells”,J. Virol. 75(13): 6223-27 (2001).
Kakkis, E.D. et al, “Enzyme-replacement therapy in mucopolysaccharidosis I”,N. Engl. J. Med. 344(3): 182-188 (2001).
Kauli, R. et al, “Delayed Growth in Puberty in Pateints with Gaucher Disease Type 1: Natural History And Effects of Splenectomy and/or Enzyme Replacement Therapy”,Isr. Med. Assoc. J. 2(2): 158-63 (2000).
Kawar, Z. et al, “Insect cells encode a class II α-Mannosidase with Unique properties”,J. Biol. Chem. 276(19): 16335-40 (2001).
Lew, D.B. et al, “Mitogenic effect of lysosomal hydrolases on bovine tracheal myocytes in culture”,J. Clin. Invest., 99: 1969-1975 (1991).
Lew, D.B. et al, “A mannose receptor mediates mannosyl-rich glycoprotein-induced mitogenesis in bovine airway smooth muscle cells”,J. Clin. Invest. 94:1855-1863 (1994).
Licari, P.J. et al, “Insect Cell Hosts for Baculovirus Expression Vectors Contain Endogenous Exoglycosidas Activity”,Biotechnol. Prog. 9:146-152 (1993).
Lin, L. et al, “Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis”,Biochem J. 357: 49-55 (2001).
Liu, Z. et al, “TNF-α and IL-1α induce mannose receptors and apoptosis in glomerular mesangial but not endothelial cells”,Am. J. Physiol. 270: C1595-1601 (1996).
Lutz, D.A. et al, “Natural, high-mannose glycoproteins inhibit ROS binding and ingestion by RPE cell cultures”,Exp. Eye Res. 61: 487-493 (1995).
Magnusson, S. et al, “Endocytosis of ricin by rat liver cells in vivo and in vitro i
Bonten Erik Jacobus
D'Azzo Alessandra
Elmer J. Scott
Fronda Christian L.
St. Jude Children's Research Hospital
LandOfFree
Method for producing proteins suitable for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for producing proteins suitable for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for producing proteins suitable for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3758340